ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1838

Fibromyalgia, Beyond the 2016 Establishment. an Analysis of Novel Symptom Clusters for Differentiating Fibromyalgia from Other Chronic Pain Disorders

Kim Jones1, Robert M. Bennett1, Amanda W. St. John2 and Ronald Friend3, 1Schools of Nursing and Medicine, Oregon Health & Science University, Portland, OR, 2Anesthesiology and Pain Medicine, Oregon Health & Science University, Portland, OR, 3School of Nursing, Oregon Health & Science University, Portland, OR

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Diagnostic criteria and fibromyalgia

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, October 22, 2018

Title: 4M082 ACR Abstract: Fibromyalgia & Other Clinical Pain Syndromes (1834–1839)

Session Type: ACR Concurrent Abstract Session

Session Time: 2:30PM-4:00PM

Background/Purpose:

Clinicians must commonly differentiate fibromyalgia (FM) from other chronic pain diagnoses. Numerous symptoms, including those from the 2016 criteria, have been proposed to accomplish this differentiation — but little is known about their relative importance. Moreover, other potential symptom candidates have been neglected. Herein we rank 26 symptoms according to how well (or not) they differentiate FM patients from other chronic pain patients. We highlight symptoms that are most important and identify others that have received little or no attention.

Methods:

The data for this study was taken from a previously published paper (2018, J of Evaluation in Clinical Practice, 24(1): 173-179). A total of 352 patients (mean age 50 ± 16.3 years, 70% female) were studied. They comprised of 52 patients (14.8%) who carried a chart diagnosis of FM, 108 (30.7%) with chronic pain but not FM, and 192 who had neither pain nor FM. All patients completed a questionnaire that documented pain at 28 locations, the Revised Symptom Impact Questionnaire (SIQR) which included 10 symptoms and 16 additional novel questions related to other common symptoms often co-occur with FM. The 26 symptoms were ranked in their capacity to predict FM vs. chronic pain no FM using the Somers’ D statistic.

Results:

These data suggests that VAS pain itself is not a useful symptom in diagnosing FM in a population of patients with chronic pain (lowest rank). The most useful clusters for differentiating FM patients from chronic pain patients without FM were: “I have a persistent deep ache over most of my body” combined with 4 other symptoms (poor balance, sensitivity to noise, environmental sensitivity and pain after exercise; Odds ratio =9.30), or the deep ache question in association with poor balance, environmental sensitivity, pain after exercise and tenderness to touch; Odds ratio =9.27). Symptoms used in the Symptom Severity Scale (SSS) of the 2016 Revised Fibromyalgia Criteria, (unrefreshing sleep, dyscognition, fatigue , IBS symptoms, depression and headache) have relatively low discriminatory value (Odds ratio= 2.96).

Conclusion: These data attest to the potential usefulness of a cluster of symptoms that are not commonly used in current diagnostic guidelines for FM. Furthermore, they are notably different from symptoms advocated in the established 2016 revised guidelines.

Somers’D (rank)

Symptom VAS

(range 0-10)

FM Mean

n=50 (rank)

Pain No FM Mean
n=108 (rank)

Mean
difference

.641 (1)

Persistent Deep Ache*

7.40 (5)

3.14 (17)

4.26

.592 (2)

Intolerance to Noise

6.98 (6)

3.27 (15)

3.71

.574 (3)

Environmental Sensitivity*

6.82 (9)

3.04 (20)

3.78

.552 (4)

Balance*

6.26 (16)

3.06 (18)

3.20

.534 (5)

Pain after Exercise*

8.08 (1)

4.07 (7)

4.01

.524 (6)

Muscles Feel Weak

6.92 (7)

3.77 (10)

3.15

.511 (7)

Tenderness to Touch*

6.82 (9)

3.61 (11)

3.21

.505 (8)

Muscle Stiffness

7.68 (3)

4.86 (4)

2.82

.492 (9)

Intolerance to Bright Lights

6.58 (13)

3.41 (14)

3.17

.491 (10)

Tender Muscles

7.90 (2)

4.94 (2)

2.96

.473 (11)

Anxiety

6.26 (15)

3.50 (12)

2.76

.453 (12)

Restless Leg Symptoms

6.02) (18)

3.02 (22)

3.00

.452 (13)

Poor Sleep†

7.54 (4)

4.60 (5)

2.94

.421 (14)

Poor Memory†

5.66 (20)

3.03 (21)

2.63

.414 (15)

Intolerance to Cold

6.62 (12)

3.82 (8)

2.80

.412 (16)

Irritable Bowel Symptoms†

5.68 (19)

3.05 (19)

2.63

.409 (17)

Swollen Joints

6.16 (17)

3.78 (9)

2.39

.398 (18)

Depression†

5.44 (22)

3.17 (16)

2.27

.396 (19)

Stiffness

6.92 (7)

4.54 (6)

2.38

.390 (20)

Chronic Headaches†

5.62 (21)

3.45 (13)

2.17

.371 (21)

Irritable Bladder Symptoms

4.36 (25)

2.25 (26)

2.11

.349 (22)

Energy (Fatigue) †

6.82 (9)

4.92 (3)

1.90

.348 (23)

Skin Bruising

4.90 (23)

2.99 (23)

1.91

.336 (24)

Abdominal Swelling

3.98 (26)

2.44 (25)

1.54

.327 (25)

Intolerance to Perfumes

4.72 (24)

2.86 (24)

1.86

.320 (26)

Pain

6.54 (14)

5.12 (1)

1.42

Symptoms (italicized) measured on Revised Symptom Impact Questionnaire (SIQR)

†symptoms measured on the Symptom Severity Scale (SSS) of the 2016 proposed fibromyalgia criteria

*5 items that best predict fibromyalgia


Disclosure: K. Jones, None; R. M. Bennett, None; A. W. St. John, None; R. Friend, None.

To cite this abstract in AMA style:

Jones K, M. Bennett R, W. St. John A, Friend R. Fibromyalgia, Beyond the 2016 Establishment. an Analysis of Novel Symptom Clusters for Differentiating Fibromyalgia from Other Chronic Pain Disorders [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/fibromyalgia-beyond-the-2016-establishment-an-analysis-of-novel-symptom-clusters-for-differentiating-fibromyalgia-from-other-chronic-pain-disorders/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/fibromyalgia-beyond-the-2016-establishment-an-analysis-of-novel-symptom-clusters-for-differentiating-fibromyalgia-from-other-chronic-pain-disorders/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology